Abstract
MicroRNA (miR)-590 is known to promote proliferation in various cancer cell lines, but its role in non-cancerous cells like human umbilical cord mesenchymal stem cells (HUMSCs) is less understood. This study investigates the effects of miR-590 on HUMSC proliferation and extracellular matrix (ECM) synthesis. Through transfection of miR-590 mimics, bioinformatic analysis, and dual-luciferase assays, we identified Smad7 as a direct target. Our findings reveal that miR-590 downregulates Smad7, leading to enhanced cell proliferation and ECM accumulation, suggesting a potential therapeutic pathway for tissue regeneration.
Introduction
Tissue repair and regeneration, particularly for chronic wounds, remain significant clinical challenges. Mesenchymal stem cells (MSCs), especially those from the umbilical cord (HUMSCs), are promising candidates for regenerative medicine due to their high self-renewal capacity and low immunogenicity. MicroRNAs are critical regulators of gene expression in wound healing. While miR-590 has been characterized as a tumor promoter, its ability to stimulate growth and matrix production in stem cells offers a novel approach to enhancing tissue repair.
Materials and Methods
HUMSCs were transfected with miR-590 mimics or siRNAs targeting specific genes. Bioinformatic tools (TargetScan, microRNA.org, miRBase) predicted potential targets, with Smad7 emerging as a primary candidate. Direct interaction was confirmed via a dual-luciferase reporter assay using the 3'-UTR of Smad7. Functional outcomes were assessed using EdU proliferation assays, Western blotting, and immunofluorescence for ECM components like Collagen I and Fibronectin.
Results
miR-590 Upregulation and Target Identification
Transfection with miR-590 mimics achieved a significant increase in microRNA levels, ranging from 66-fold to 138-fold compared to controls.
Bioinformatic analysis and luciferase assays confirmed that miR-590 directly targets the 3'-UTR of Smad7. Overexpression of miR-590 resulted in a ~51.55% reduction in Smad7 mRNA and a corresponding decrease in Smad7 protein levels.
Enhanced Proliferation and ECM Synthesis
The reduction of Smad7—a known inhibitor of the TGF-β pathway—effectively accelerated the cell cycle. Proliferation rates increased to 38.15% and 60.14% with 50 nM and 100 nM miR-590 treatments, respectively.
Furthermore, ECM accumulation was significantly boosted, with Collagen I and Fibronectin levels increasing by up to 52% and 152%, respectively. Morphologically, HUMSCs transitioned toward a fibroblast-like appearance, indicative of active matrix deposition.
Discussion
This study demonstrates that miR-590 acts as a molecular switch to promote HUMSC activity by silencing Smad7. By removing this "brake" on the TGF-β signaling pathway, miR-590 induces a high-growth state conducive to wound repair. The observation that Smad7 siRNA mimics the effects of miR-590 overexpression confirms Smad7 as the central mediator of these effects.
However, several considerations remain. These in vitro findings must be validated in vivo to account for complex physiological environments. Additionally, given miR-590's known role in oncogenesis, therapeutic applications must ensure precise control to avoid tumorigenic risks.
Conclusion
miR-590 significantly enhances the proliferative and biosynthetic capabilities of HUMSCs by targeting Smad7. This mechanism highlights miR-590 as a potential target for developing advanced stem cell therapies in regenerative medicine.
Summary updated